Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Genetic transfer of a nonpeptide antagonist binding site to a previously unresponsive angiotensin receptor.
Ji H
,
Zheng W
,
Zhang Y
,
Catt KJ
,
Sandberg K
.
???displayArticle.abstract???
Mutational analysis based on the pharmacological differences between mammalian and amphibian angiotensin II receptors (AT receptors) previously identified 7 aa residues located in transmembrane domains (TMs) III (Val-108), IV (Ala-163), V (Pro-192, Thr-198), VI (Ser-252), and VII (Leu-300, Phe-301) of the rat AT receptor type 1b (rAT1b receptor) that significantly influenced binding of the nonpeptide antagonist Losartan. Further studies have shown that an additional 6 residues in the rAT1b receptor TMs II (Ala-73), III (Ser-109, Ala-114, Ser-115), VI (Phe-248), and VII (Asn-295) are important in Losartan binding. The 13 residues required for Losartan binding in the mammalian receptor were exchanged for the corresponding amino acids in the Xenopus AT receptor type a (xATa receptor) to generate a mutant amphibian receptor that bound Losartan with the same affinity as the rAT1b receptor (Losartan IC50 values: rAT1b, 2.2 +/- 0.2 nM: xATa, > 50 microM; mutant, 2.0 +/- 0.1 nM). To our knowledge, this is the first report of a gain-of-function mutant in which the residues crucial to formation of a ligand binding site in a mammalian peptide hormone receptor were transferred to a previously unresponsive receptor by site-directed mutagenesis. Ala substitutions and comparison of mammalian and amphibian combinatorial mutants indicated that TM III in the rAT1b receptor plays a key role in Losartan binding. Identification of residues involved in nonpeptide ligand binding will facilitate studies aimed at elucidating the chemical basis for ligand recognition in the AT receptor and peptide hormone receptors in general.
Elling,
Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor.
1995, Pubmed
Elling,
Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor.
1995,
Pubmed
Fong,
Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor.
1992,
Pubmed
,
Xenbase
Gerszten,
Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface.
1994,
Pubmed
,
Xenbase
Gether,
Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist.
1993,
Pubmed
Groblewski,
Amino acids of the third transmembrane domain of the AT1A angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands.
1995,
Pubmed
Hjorth,
Identification of peptide binding residues in the extracellular domains of the AT1 receptor.
1994,
Pubmed
Ji,
Novel angiotensin II antagonists distinguish amphibian from mammalian angiotensin II receptors expressed in Xenopus laevis oocytes.
1991,
Pubmed
,
Xenbase
Ji,
Molecular cloning, sequencing and functional expression of an amphibian angiotensin II receptor.
1993,
Pubmed
,
Xenbase
Ji,
Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan.
1994,
Pubmed
Lee,
Lysine 182 of endothelin B receptor modulates agonist selectivity and antagonist affinity: evidence for the overlap of peptide and non-peptide ligand binding sites.
1994,
Pubmed
Murphy,
A cloned angiotensin receptor isoform from the turkey adrenal gland is pharmacologically distinct from mammalian angiotensin receptors.
1993,
Pubmed
Noda,
Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms.
1995,
Pubmed
Nouet,
Properties of [3H]LF 7-0156, a new nonpeptide antagonist radioligand for the type 1 angiotensin II receptor.
1994,
Pubmed
Perlman,
Hydrogen bonding interaction of thyrotropin-releasing hormone (TRH) with transmembrane tyrosine 106 of the TRH receptor.
1994,
Pubmed
Rosenkilde,
Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding.
1994,
Pubmed
Sachais,
Molecular basis for the species selectivity of the substance P antagonist CP-96,345.
1993,
Pubmed
Sandberg,
Amphibian myocardial angiotensin II receptors are distinct from mammalian AT1 and AT2 receptor subtypes.
1991,
Pubmed
,
Xenbase
Sandberg,
Cloning and expression of a novel angiotensin II receptor subtype.
1992,
Pubmed
,
Xenbase
Savarese,
In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors.
1992,
Pubmed
Schambye,
Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors.
1994,
Pubmed
,
Xenbase
Schwartz,
Locating ligand-binding sites in 7TM receptors by protein engineering.
1994,
Pubmed
Strader,
Structure and function of G protein-coupled receptors.
1994,
Pubmed
Strader,
Structural basis of beta-adrenergic receptor function.
1989,
Pubmed
Timmermans,
Angiotensin II receptors and angiotensin II receptor antagonists.
1993,
Pubmed
Underwood,
Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor.
1994,
Pubmed
Zhu,
Replacement of lysine-181 by aspartic acid in the third transmembrane region of endothelin type B receptor reduces its affinity to endothelin peptides and sarafotoxin 6c without affecting G protein coupling.
1992,
Pubmed